Skip to main content
Year archive

Zelluna ASA — 2022 filings

All 68 regulatory filings released by Zelluna ASA (ULTI) in 2022, sourced directly from the official regulator.

68 Filings
2022 Period
2022 filings (68)
Filing Released Lang
Financial calendar
Report Publication Announcement
2022-12-21 English
Cemiplimab to replace pembrolizumab in UV1 Phase II LUNGVAC Trial
Regulatory Filings
2022-12-20 English
Ultimovacs Announces Completed Patient Recruitment in TENDU Phase I Clinical Trial in Prostate Cancer
Regulatory Filings
2022-12-14 English
Ultimovacs ASA: Mandatory notification of trade by primary insider
Director's Dealing
2022-11-29 English
Ultimovacs ASA: Mandatory notification of trade by primary insider
Director's Dealing
2022-11-29 English
Ultimovacs ASA: New share capital registered
Share Issue/Capital Change
2022-11-21 English
Ultimovacs ASA: Share capital increase related to exercise of options
Share Issue/Capital Change
2022-11-16 English
Ultimovacs ASA: Mandatory notification of trade by primary insider
Director's Dealing
2022-11-10 English
Ultimovacs ASA: Mandatory notification of trade by primary insider
Director's Dealing
2022-11-10 English
Ultimovacs ASA Reports Third Quarter 2022 Financial Results and Provides General Business Update
Investor Presentation Q3 2022
2022-11-10 English
Ultimovacs ASA Reports Third Quarter 2022 Financial Results and Provides General Business Update
Interim / Quarterly Report Q3 2022
2022-11-10 English
Ultimovacs ASA Reports Third Quarter 2022 Financial Results and Provides General Business Update
Earnings Release Q3 2022
2022-11-10 English
Ultimovacs ASA: Invitation to Third quarter 2022 results webcast presentation
Report Publication Announcement
2022-11-03 English
Ultimovacs Announces First Patient Randomized in Phase II LUNGVAC Trial of UV1 in Non-Small Cell Lung Cancer (NSCLC)
Regulatory Filings
2022-10-25 English
Ultimovacs Announces New UV1 Data Showing Enhanced Efficacy Including in Hard-to-Treat Cancer Patients, Supporting Broad Utility
Regulatory Filings
2022-10-18 English
Ultimovacs Announces Positive Three-Year Results of 71% Overall Survival Rate in Cohort 1 of UV1-103 Study in Metastatic Malignant Melanoma
Earnings Release Q4 2022
2022-10-05 English
Ultimovacs Announces Plenary Oral Presentation of Phase I Melanoma Trial Results at the 19th International Congress of the Society for Melanoma Research (SMR)
Regulatory Filings
2022-09-21 English
Ultimovacs Announces Publication of Phase I Melanoma Trial Data in Journal of Translational Medicine
Report Publication Announcement
2022-09-12 English
Ultimovacs ASA: New share capital registered
Share Issue/Capital Change
2022-09-09 English
Ultimovacs ASA: Mandatory notification of trade by primary insider
Director's Dealing
2022-09-05 English
Ultimovacs ASA: Mandatory notification of trade by primary insider
Director's Dealing
2022-09-05 English
Ultimovacs ASA: Share capital increase related to exercise of options
Share Issue/Capital Change
2022-09-05 English
Ultimovacs Strengthens IP Portfolio with the United States Patent and Trademark Office (USPTO) Notice of Allowance on UV1 Method Patent
Regulatory Filings
2022-08-22 English
Ultimovacs ASA Reports Second Quarter 2022 Financial Results and Provides General Business Update
Investor Presentation
2022-08-19 English
Ultimovacs ASA Reports Second Quarter 2022 Financial Results and Provides General Business Update
Interim / Quarterly Report Q2 2022
2022-08-19 English
Ultimovacs ASA Reports Second Quarter 2022 Financial Results and Provides General Business Update
Earnings Release Q2 2022
2022-08-19 English
Ultimovacs Expands High Dose Cohort Size in TENDU Phase I Prostate Cancer Trial after Safety Review
Regulatory Filings
2022-08-18 English
Ultimovacs ASA: Invitation to second quarter 2022 results webcast presentation
Report Publication Announcement
2022-08-12 English
Ultimovacs ASA: Mandatory notification of trade by primary insider
Director's Dealing
2022-06-30 English
Ultimovacs ASA: Mandatory notification of trade by primary insider
Director's Dealing
2022-06-30 English
Ultimovacs Completes Patient Recruitment in INITIUM Phase II Trial of UV1 in Malignant Melanoma
Regulatory Filings
2022-06-30 English
Ultimovacs' UV1 cancer vaccine shows strong overall survival in malignant melanoma phase I trial
Regulatory Filings
2022-06-20 English
Ultimovacs' Clinical Data in Journal for ImmunoTherapy of Cancer Show Long-term Dynamic T Cell Responses with UV1 and Checkpoint Inhibitor Synergy
Regulatory Filings
2022-05-25 English
Ultimovacs ASA: First quarter 2022 result presentation
Investor Presentation
2022-05-12 English
Ultimovacs ASA: First quarter 2022 result presentation
Interim / Quarterly Report Q1 2022
2022-05-12 English
Ultimovacs ASA: First quarter 2022 result presentation
Earnings Release Q1 2022
2022-05-12 English
Ultimovacs Announces Presentation of UV1 Immune Monitoring Data at Cancer Immunotherapy Annual Meeting
Environmental & Social Information
2022-05-10 English
Ultimovacs ASA: Invitation to first quarter 2022 results webcast presentation
Report Publication Announcement
2022-05-05 English
Ultimovacs Receives Notice of Allowance on US Patent on Vaccine-Checkpoint Inhibitor Combinations
Regulatory Filings
2022-04-22 English
Ultimovacs ASA - Share Option Program
Remuneration Information
2022-04-21 English
Ultimovacs ASA - Annual General Meeting held on 21 April 2022
AGM Information
2022-04-21 Norwegian
Ultimovacs ASA - Annual General Meeting held on 21 April 2022
AGM Information
2022-04-21 English
Ultimovacs Presents TET Platform Pre-Clinical Data at AACR 2022 Supporting Clinical Development
Regulatory Filings
2022-04-08 English
Ultimovacs ASA - Disclosure of voting rights of Annual General Meeting
Declaration of Voting Results & Voting Rights Announcements
2022-04-08 English
Ultimovacs to host Investor Days 2022: Meet the Team
Investor Presentation
2022-03-30 English
Correction: Ultimovacs ASA: Annual Report 2021
Annual Report (ESEF) FY 2021
2022-03-25 English
Correction: Ultimovacs ASA: Annual Report 2021
Annual Report FY 2021
2022-03-25 English
Correction: Ultimovacs ASA: Annual Report 2021
Report Publication Announcement FY 2021
2022-03-25 English
Ultimovacs ASA: Notice of Annual General Meeting on 21 April 2022
Governance Information
2022-03-25 English
Ultimovacs ASA: Notice of Annual General Meeting on 21 April 2022
Remuneration Information
2022-03-25 English
Ultimovacs ASA: Notice of Annual General Meeting on 21 April 2022
Remuneration Information
2022-03-25 English
Ultimovacs ASA: Notice of Annual General Meeting on 21 April 2022
Remuneration Information
2022-03-25 English
Ultimovacs ASA: Notice of Annual General Meeting on 21 April 2022
Annual Report FY 2021
2022-03-25 English
Ultimovacs ASA: Notice of Annual General Meeting on 21 April 2022
AGM Information
2022-03-25 English
Ultimovacs ASA: Notice of Annual General Meeting on 21 April 2022
AGM Information
2022-03-25 English
Ultimovacs ASA: Notice of Annual General Meeting on 21 April 2022
AGM Information
2022-03-25 English
Ultimovacs ASA: Annual Report 2021
Annual Report (ESEF) FY 2021
2022-03-25 English
Ultimovacs ASA: Annual Report 2021
Annual Report FY 2021
2022-03-25 English
Ultimovacs ASA: Annual Report 2021
Report Publication Announcement
2022-03-25 English
Ultimovacs Hosting Key Opinion Leader Webinar on the Evolving Treatment Landscape of Melanoma
Regulatory Filings
2022-03-21 English
Ultimovacs to Present Preclinical Data on TET Platform at American Association for Cancer Research (AACR) 2022 Annual Meeting
Regulatory Filings
2022-03-09 English
Ultimovacs ASA: Mandatory notification of trade by primary insider
Director's Dealing
2022-02-17 English
Ultimovacs ASA: Mandatory notification of trade by primary insider
Director's Dealing
2022-02-17 English
Ultimovacs ASA: Fourth quarter 2021 result presentation
Investor Presentation
2022-02-17 English
Ultimovacs ASA: Fourth quarter 2021 result presentation
Interim / Quarterly Report Q4 2021
2022-02-17 English
Ultimovacs ASA: Fourth quarter 2021 result presentation
Earnings Release Q4 2021
2022-02-17 English
Ultimovacs ASA: Invitation to fourth quarter 2021 results webcast presentation
Report Publication Announcement
2022-02-10 English
Ultimovacs to Progress to Last Cohort in Phase I Prostate Cancer TENDU study
Regulatory Filings
2022-02-03 English